• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    Ancestry.Com Moves Further Into Consumer Genetics With Launch of AncestryHealth

    Morag Mcgreevey
    Jul. 16, 2015 09:48AM PST
    Genetics Investing

    The MIT Technology Review reports that Ancestry.Com’s (NASDAQ:ACOM) launch of AncestryHealth will further position the company as a player in the consumer genetics market.

    The MIT Technology Review reports that Ancestry.Com’s (NASDAQ:ACOM) launch of AncestryHealth will further position the company as a player in the consumer genetics market.
    According to the article:

    With the Thursday launch of its AncestryHealth website, Ancestry continues to play Microsoft to 23andMe’s Apple. It may not be as innovative in the burgeoning field of consumer genetics, but it’s an able competitor nonetheless.
    Ancestry entered the field of consumer DNA analysis in 2012 with the launch of AncestryDNA, a $99 spit test that will analyze your DNA for details about your ethnic makeup and connect you with distant relatives. This was five years after 23andMe began to offer similar DNA-testing kits.
    […] The FDA cracked the door in February to allow 23andMe to market a direct-to-consumer genetic test for Bloom syndrome, and it seems likely that both Ancestry and 23andMe may try to move in the direction of tailoring their tests to specific diseases, depending on the FDA’s signals.

    Click here to read the full article on MIT Technology Review.
     

     

    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    hand holding dna helix

    How to Invest in Genetics

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×